5 Things You Should Know About Bharat Biotech’s COVID-19 Vaccine – Covaxin
Here are some crucial things you need to know about Bharat Biotech’s Coronavirus vaccine, Covaxin.
Bharat Biotech’s Covaxin is currently in its clinical trial mode. Phase 3 trials of Bharat Biotech’s vaccine are still going on but it has already received the go-ahead for restricted emergency usage in India. Thus, here are 5 things we believe you should know about it.
Watch the video here:
1. When will Covaxin be rolled out?
A lot of people might be curious as to when the vaccine will be rolled out for usage. Dr. Krishna Ella, MD of Bharat Biotech, mentioned that they would love to launch the vaccine as soon as possible for the benefit of the people. However, he added that it is not under their control at the moment as they have already sent out the batches of the vaccine to Kasauli, Himachal Pradesh.
2. Cost of Bharat Biotech’s Covaxin
The cost of the vaccine is going to be another major concern for people. Dr. Krishna Ella said that the cost of the vaccine might rank slightly higher in the market of vaccines initially. However, he added that as the production of Covaxin increases, and so does the competition in the market, the price will get moderated and drop lower automatically.
3. Will Covaxin protect against the new strain?
Many people have been wondering if the vaccine will be effective on the new strain of the Coronavirus. And Bharat Biotech has declared and confirmed that Covaxin will work effectively on the new strain as well. The vaccine is supposed to be very effective against fresh mutations of the virus.
4. Total number of doses to be produced
The number of doses of the vaccine to be rolled out is now at the mark of 20 million. However, the MD of Bharat Biotech revealed that they are aiming to reach a full capacity of approximately 700 million doses in a total of 4 facilities in India, 3 of which are in Hyderabad and 1 in Bengaluru.
5. Covaxin’s side effects
A major concern of many people is if the Covaxin will have any side effects on a candidate. To clarify this doubt, Dr. Krishna said that while going into Phase 3 of the trials, they found less than 10% of adverse reactions or side effects. He also stated that they have vaccinated around 24,000 people.
Stay updated with the latest COVID-19 news only on ZEE5!